id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
DEA-2016-0008-0004,DEA,DEA-2016-0008,Schedules of Controlled Substances: Placement of Brivaracetam into Schedule V,Rule,,2017-03-09T05:00:00Z,2017,3,2017-03-09T05:00:00Z,,2017-03-09T14:59:57Z,2017-04698,0,0,09000064824fb4ab
DEA-2016-0008-0003,DEA,DEA-2016-0008,DEA Background Data and Analysis_Brivaracetam_Dec2015,Supporting & Related Material,,2016-05-12T04:00:00Z,2016,5,,,2016-05-12T16:36:37Z,,0,0,0900006481fc9201
DEA-2016-0008-0001,DEA,DEA-2016-0008,Schedules of Controlled Substances: Placement of Brivaracetam into Schedule V,Rule,,2016-05-12T04:00:00Z,2016,5,2016-05-12T04:00:00Z,2016-06-14T03:59:59Z,2016-05-12T15:17:08Z,2016-11245,0,0,0900006481fc79f2
DEA-2016-0008-0002,DEA,DEA-2016-0008,DEA 435_brivaracetam_HHS 09 08 2015,Supporting & Related Material,,2016-05-12T04:00:00Z,2016,5,,,2016-05-12T15:36:23Z,,0,0,0900006481fc8c29